{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:25:26Z","timestamp":1791275126301,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,8,19]],"date-time":"2010-08-19T00:00:00Z","timestamp":1282176000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2010,8,19]],"date-time":"2010-08-19T00:00:00Z","timestamp":1282176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Purpura fulminans (PF) is a devastating complication of uncontrolled systemic inflammation, associated with high incidence of amputations, skin grafts and death. In this study, we aimed to clarify the clinical profile of pediatric patients with PF who improved with protein C (PC) treatment, explore treatment effects and safety, and to refine the prognostic significance of protein C plasma levels.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>In Germany, patients receiving protein C concentrate (Ceprotin<jats:sup>\u00ae<\/jats:sup>, Baxter AG, Vienna, Austria) are registered. The database was used to locate all pediatric patients with PF treated with PC from 2002 to 2005 for this national, retrospective, multi-centered study.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Complete datasets were acquired in 94 patients, treated in 46 centers with human, non-activated protein C concentrate for purpura fulminans. PC was given for 2 days (median, range 1-24 days) with a median daily dose of 100 IU\/kg. Plasma protein C levels increased from a median of 27% to a median of 71% under treatment. 22.3% of patients died, 77.7% survived to discharge. Skin grafts were required in 9.6%, amputations in 5.3%. PF recovered or improved in 79.8%, remained unchanged in 13.8% and deteriorated in 6.4%. Four adverse events occurred in 3 patients, none classified as severe. Non-survivors had lower protein C plasma levels (<jats:italic>P<\/jats:italic> &lt; 0.05) and higher prevalence of coagulopathy at admission (<jats:italic>P<\/jats:italic> &lt; 0.01). Time between admission and start of PC substitution was longer in patients who died compared to survivors (<jats:italic>P<\/jats:italic> = 0.03).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>This retrospective dataset shows that, compared to historic controls, only few pediatric patients with PF under PC substitution needed dermatoplasty and\/or amputations. Apart from epistaxis, no bleeding was observed. Although the data comes from a retrospective study, the evidence we present suggests that PC had a beneficial impact on the need for dermatoplasty and amputations, pointing to the potential value of carrying out a prospective randomised controlled trial.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/cc9226","type":"journal-article","created":{"date-parts":[[2010,8,19]],"date-time":"2010-08-19T20:15:54Z","timestamp":1282248954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Human protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patients"],"prefix":"10.1186","volume":"14","author":[{"given":"Alex","family":"Veldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora Y","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfhart","family":"Kreuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Ebersp\u00e4cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Mansmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Schosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,8,19]]},"reference":[{"key":"8633_CR1","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199111283252207","volume":"325","author":"M Dreyfus","year":"1991","unstructured":"Dreyfus M, Magny JF, Bridey F, Schwarz HP, Planche C, Dehan M, Tchernia G: Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate.\n                           N Engl J Med 1991, 325: 1565-1568. 10.1056\/NEJM199111283252207","journal-title":"N Engl J Med"},{"key":"8633_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1046\/j.1365-2141.2003.03983_2.x","volume":"120","author":"PM Baker","year":"2003","unstructured":"Baker PM, Keeling DM, Murphy M: Plasma exchange as a source of protein C for acute-onset protein C pathway failure.\n                           Br J Haematol 2003, 120: 167-168. 10.1046\/j.1365-2141.2003.03983_2.x","journal-title":"Br J Haematol"},{"key":"8633_CR3","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1182\/blood.V96.12.3719","volume":"96","author":"B White","year":"2000","unstructured":"White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP: An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia.\n                           Blood 2000, 96: 3719-3724.","journal-title":"Blood"},{"key":"8633_CR4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1055\/s-2007-994962","volume":"25","author":"CE Ettingshausen","year":"1999","unstructured":"Ettingshausen CE, Veldmann A, Beeg T, Schneider W, Jager G, Kreuz W: Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans.\n                           Semin Thromb Hemost 1999, 25: 537-541. 10.1055\/s-2007-994962","journal-title":"Semin Thromb Hemost"},{"key":"8633_CR5","doi-asserted-by":"publisher","first-page":"R331","DOI":"10.1186\/cc3538","volume":"9","author":"JL Vincent","year":"2005","unstructured":"Vincent JL, Nadel S, Kutsogiannis DJ, Gibney RT, Yan SB, Wyss VL, Bailey JE, Mitchell CL, Sarwat S, Shinall SM, Janes JM: Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.\n                           Crit Care 2005, 9: R331-343. 10.1186\/cc3538","journal-title":"Crit Care"},{"key":"8633_CR6","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1097\/01.CCM.0000072121.61120.D8","volume":"31","author":"ED de Kleijn","year":"2003","unstructured":"de Kleijn ED, de Groot R, Hack CE, Mulder PG, Engl W, Moritz B, Joosten KF, Hazelzet JA: Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study.\n                           Crit Care Med 2003, 31: 1839-1847. 10.1097\/01.CCM.0000072121.61120.D8","journal-title":"Crit Care Med"},{"key":"8633_CR7","doi-asserted-by":"publisher","first-page":"5824","DOI":"10.1021\/bi00645a029","volume":"16","author":"W Kisiel","year":"1977","unstructured":"Kisiel W, Canfield WM, Ericsson LH, Davie EW: Anticoagulant properties of bovine plasma protein C following activation by thrombin.\n                           Biochemistry 1977, 16: 5824-5831. 10.1021\/bi00645a029","journal-title":"Biochemistry"},{"key":"8633_CR8","doi-asserted-by":"publisher","first-page":"11199","DOI":"10.1074\/jbc.C100017200","volume":"276","author":"DE Joyce","year":"2001","unstructured":"Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW: Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis.\n                           J Biol Chem 2001, 276: 11199-11203. 10.1074\/jbc.C100017200","journal-title":"J Biol Chem"},{"key":"8633_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nm826","volume":"9","author":"T Cheng","year":"2003","unstructured":"Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED, Fukudome K, Zlokovic BV: Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective.\n                           Nat Med 2003, 9: 338-342. 10.1038\/nm826","journal-title":"Nat Med"},{"key":"8633_CR10","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1126\/science.1071699","volume":"296","author":"M Riewald","year":"2002","unstructured":"Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W: Activation of endothelial cell protease activated receptor 1 by the protein C pathway.\n                           Science 2002, 296: 1880-1882. 10.1126\/science.1071699","journal-title":"Science"},{"key":"8633_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/adc.85.5.386","volume":"85","author":"R Booy","year":"2001","unstructured":"Booy R, Habibi P, Nadel S, de Munter C, Britto J, Morrison A, Levin M: Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery.\n                           Arch Dis Child 2001, 85: 386-390. 10.1136\/adc.85.5.386","journal-title":"Arch Dis Child"},{"key":"8633_CR12","doi-asserted-by":"publisher","first-page":"R112","DOI":"10.1186\/cc6161","volume":"11","author":"M Maat","year":"2007","unstructured":"Maat M, Buysse CM, Emonts M, Spanjaard L, Joosten KF, de Groot R, Hazelzet JA: Improved survival of children with sepsis and purpura: effects of age, gender, and era.\n                           Crit Care 2007, 11: R112. 10.1186\/cc6161","journal-title":"Crit Care"},{"key":"8633_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/ajh.20435","volume":"80","author":"A Gurgey","year":"2005","unstructured":"Gurgey A, Aytac S, Kanra G, Secmeer G, Ceyhan M, Altay C: Outcome in children with purpura fulminans: report on 16 patients.\n                           Am J Hematol 2005, 80: 20-25. 10.1002\/ajh.20435","journal-title":"Am J Hematol"},{"key":"8633_CR14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1053\/jpsu.2003.50130","volume":"38","author":"JS Wheeler","year":"2003","unstructured":"Wheeler JS, Anderson BJ, De Chalain TM: Surgical interventions in children with meningococcal purpura fulminans--a review of 117 procedures in 21 children.\n                           J Pediatr Surg 2003, 38: 597-603. 10.1053\/jpsu.2003.50130","journal-title":"J Pediatr Surg"},{"key":"8633_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/adc.2007.131862","volume":"94","author":"CM Buysse","year":"2009","unstructured":"Buysse CM, Oranje AP, Zuidema E, Hazelzet JA, Hop WC, Diepstraten AF, Joosten KF: Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock.\n                           Arch Dis Child 2009, 94: 381-386. 10.1136\/adc.2007.131862","journal-title":"Arch Dis Child"},{"key":"8633_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/BCR.0b013e3181667936","volume":"29","author":"Z Hassan","year":"2008","unstructured":"Hassan Z, Mullins RF, Friedman BC, Shaver JR, Alam B, Mian MA: Purpura fulminans: a case series managed at a regional burn center.\n                           J Burn Care Res 2008, 29: 411-415. 10.1097\/BCR.0b013e3181667936","journal-title":"J Burn Care Res"},{"key":"8633_CR17","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/j.1651-2227.2009.01404.x","volume":"98","author":"D Fischer","year":"2009","unstructured":"Fischer D, Schloesser RL, Nold-Petry CA, Nold MF, Veldman A: Protein C concentrate in preterm neonates with sepsis.\n                           Acta Paediatr 2009, 98: 1526-1529. 10.1111\/j.1651-2227.2009.01404.x","journal-title":"Acta Paediatr"},{"key":"8633_CR18","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S0140-6736(05)60653-8","volume":"351","author":"W Kreuz","year":"1998","unstructured":"Kreuz W, Veldman A, Escuriola-Ettingshausen C, Schneider W, Beeg T: Protein-C concentrate for meningococcal purpura fulminans.\n                           Lancet 1998, 351: 986-987. author reply 988","journal-title":"Lancet"},{"key":"8633_CR19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1046\/j.0007-1048.2002.03353.x","volume":"116","author":"A Hodgson","year":"2002","unstructured":"Hodgson A, Ryan T, Moriarty J, Mellotte G, Murphy C, Smith OP: Plasma exchange as a source of protein C for acute onset protein C pathway failure.\n                           Br J Haematol 2002, 116: 905-908. 10.1046\/j.0007-1048.2002.03353.x","journal-title":"Br J Haematol"},{"key":"8633_CR20","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S0140-6736(07)60411-5","volume":"369","author":"S Nadel","year":"2007","unstructured":"Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B, REsearching severe Sepsis and Organ dysfunction in children: Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial a gLobal perspective (RESOLVE) study group.\n                           Lancet 2007, 369: 836-843. 10.1016\/S0140-6736(07)60411-5","journal-title":"Lancet"},{"key":"8633_CR21","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1097\/INF.0b013e3180f616f0","volume":"26","author":"S Venkataseshan","year":"2007","unstructured":"Venkataseshan S, Dutta S, Ahluwalia J, Narang A: Low plasma protein C values predict mortality in low birth weight neonates with septicemia.\n                           Pediatr Infect Dis J 2007, 26: 684-688. 10.1097\/INF.0b013e3180f616f0","journal-title":"Pediatr Infect Dis J"},{"key":"8633_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1185\/030079906X162737","volume":"23","author":"FR Ernst","year":"2007","unstructured":"Ernst FR, Johnston JA, Pulgar S, He J, Ball DE, Young JK, Cooper LM: Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.\n                           Curr Med Res Opin 2007, 23: 235-244. 10.1185\/030079906X162737","journal-title":"Curr Med Res Opin"},{"key":"8633_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/01.CCM.0000298309.73776.CB","volume":"36","author":"A Wheeler","year":"2008","unstructured":"Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde-Zwirble W, Bates B, Qualy RL, Woodward B, Zeckel M: A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.\n                           Crit Care Med 2008, 36: 14-23. 10.1097\/01.CCM.0000298309.73776.CB","journal-title":"Crit Care Med"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/cc9226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/cc9226\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/cc9226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T12:18:03Z","timestamp":1728303483000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/cc9226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,19]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2010,8]]}},"alternative-id":["8633"],"URL":"https:\/\/doi.org\/10.1186\/cc9226","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,19]]},"assertion":[{"value":"21 April 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R156"}}